TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Merck & Company (MRK)

NYSE:MRK

Merck & Company (MRK)

130.20
+0.41 (0.32%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
311 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Merck & Company (MRK) is recognized for its strong performance, particularly bolstered by its cancer treatment drug, Keytruda, which is a significant revenue driver but faces a looming patent cliff. Despite concerns regarding the future of Keytruda, many experts are optimistic about the company's robust drug pipeline and strategic acquisitions that should help mitigate the risks associated with the loss of this key drug. The consensus among analysts suggests solid revenue growth potential, with expectations that the company will release a considerable number of new drugs by 2030. Additionally, Merck is committed to returning capital to shareholders, which includes stock buybacks and steady dividends, positioning the company as a quality investment in the healthcare sector.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Pfizer, PFE
DON'T BUY

Merck & Company(MRK)

Apr 22, 2002
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$56.52

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Apr 19, 2002
Fairly cheap. Dividend. Several drugs coming off patent.
Photo of Brad WillockBrad WillockUnlock Rating
$56.94

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Apr 15, 2002
At a 5 year low. Have some good products. At a good price.
Photo of Neil MurdockNeil MurdockUnlock Rating
$54.53

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Merck & Company(MRK)

Apr 12, 2002
Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.
Photo of David BaskinDavid BaskinUnlock Rating
$54.00

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Merck & Company(MRK)

Apr 04, 2002
One of the cheapest in the drug sctor.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$58.80

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Mar 08, 2002
Losing a lot of their patents with nothing new in the pipeline.
Photo of David DriscollDavid DriscollUnlock Rating
$62.50

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Merck & Company(MRK)

Feb 22, 2002
No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.
Photo of Brad WillockBrad WillockUnlock Rating
$61.42

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Jan 30, 2002
Broke through a technical base. Generics are giving some tough competition.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$58.84

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Jan 07, 2002
A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.
Photo of Neil MurdockNeil MurdockUnlock Rating
$58.10

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Merck & Company(MRK)

Dec 18, 2001
Competition. Pipeline is weak now. OK long term.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$58.50

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$66.99

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Nov 12, 2001
Has been a defensive stock. Overvalued.
Photo of David BurrowsDavid BurrowsUnlock Rating
$64.38

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Jun 14, 2001
Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$73.90

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jun 06, 2001
Likes both Pfizer and Merck in pharmaceuticals.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$73.95

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jun 05, 2001
Just came off a good technical support.
Photo of Ross HealyRoss HealyUnlock Rating
$75.33

Stock price when the opinion was issued

$130.20

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 286 to 300 of 307 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like